Abstract
Tumor necrosis factor-alpha (TNF-α) antagonist treatment is associated with 1.6 to 27 times higher risk of tuberculosis (TB). To find TB incidence of psoriasis patients treated with TNF- α antagonists and define risk factors related with this condition in a country with moderately high risk of TB. Three hundred seventy psoriasis patients treated by anti-TNF agents in four referral centers were included. The data on the characteristics of the patients, TB history, tuberculosis skin test results, anti-TNF agent type and exposure time, localization of TB, and isoniazide prophylaxis state were analyzed. Four patients (1.08%) developed TB, three pulmonary and one gastrointestinal, 2-23 months after initiating anti-TNF agents. Other than the patient with gastrointestinal TB, who was using methotrexate and corticosteroid concomitantly, none had contributing risk factors for TB. Two patients developed pulmonary TB in spite of chemoprophylaxis. Three patients with pulmonary TB completely recovered following antiTB treatment whereas patients with gastroinrestinal TB developed renal failure. The major limitation of the study is the lack of a diseased control group, which enables us to compare the risk of psoriatics with that of patients h...Continue Reading
References
Oct 13, 2001·The New England Journal of Medicine·J KeaneM M Braun
Aug 9, 2003·Arthritis and Rheumatism·Juan J Gómez-ReinoUNKNOWN BIOBADASER Group
Feb 12, 2004·Arthritis and Rheumatism·Frederick WolfeKathy Urbansky
Jun 30, 2005·Arthritis and Rheumatism·Johan AsklingNils Feltelius
Mar 1, 2006·Expert Opinion on Drug Safety·Eric J Forget, Dick Menzies
Jul 3, 2008·Annals of Internal Medicine·Madhukar PaiDick Menzies
Aug 13, 2008·Journal of the American Academy of Dermatology·Claudia HernandezJune K Robinson
Aug 19, 2008·Autoimmunity Reviews·Ajit Lalvani, Kerry A Millington
Dec 5, 2008·Clinical Rheumatology·Osman ElbekOner Dikensoy
Jan 17, 2009·Annals of the Rheumatic Diseases·G R BurmesterA L Pangan
Jun 18, 2009·The American Journal of Gastroenterology·Josh MarehbianWilliam J Sandborn
Jul 1, 2009·Arthritis and Rheumatism·F TubachUNKNOWN Research Axed on Tolerance of Biotherapies Group
Aug 8, 2009·The British Journal of Dermatology·E LaffitteJ-H Saurat
Oct 22, 2009·Rheumatology International·Tulin CagatayZeki Kilicaslan
Oct 27, 2009·Annals of the Rheumatic Diseases·W G DixonUNKNOWN BSR Biologics Register
May 14, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·A I Sánchez-Moya, E Dauden
Sep 13, 2011·Médecine et maladies infectieuses·N MrozekH Laurichesse
Jan 20, 2012·Annals of the Rheumatic Diseases·Xavier MariettePhilippe Ravaud
Nov 9, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·A I Sánchez-MoyaUNKNOWN BIOBADADERM Study Group
Citations
Jun 4, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·E GuinardUNKNOWN French Psoriasis Research Group
Apr 23, 2016·PloS One·Hye Won KimUNKNOWN Korean Society of Spondyloarthritis Research
Mar 18, 2017·Journal of Applied Microbiology·V B PereiraA Miyoshi
Nov 7, 2017·International Journal of Molecular Sciences·Kirsten Rønholt, Lars Iversen
Feb 13, 2018·Disease Markers·Ying ZhouHong-Qi Zhang
Mar 29, 2019·American Journal of Clinical Dermatology·Igor SnastLev Pavlovsky
Feb 6, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·E FowlerJ J Wu
May 28, 2020·Dermatologic Therapy·Jose W Ricardo, Shari R Lipner
Sep 5, 2017·Clinical & Translational Immunology·Michael KammüllerTodd Fox
Jun 20, 2019·Dermatology Research and Practice·Asmah JoharKwee Eng Tey
Dec 4, 2020·PloS One·Vanessa Lucília Silveira de MedeirosVera Magalhães
Mar 22, 2021·Clinical Rheumatology·Yagmur KaptanAbdullah Sayiner
Oct 31, 2019·Case Reports in Dermatology·Simone RiberoPaolo Dapavo